Hoth Therapeutics, Inc. announced that Michael H. Peters, Ph.D., has joined the company's Scientific Advisory Board. Dr. Peters is the inventor of Hoth's newly licensed Novel Peptide COVID-19 Therapeutic, to prevent spike protein binding, which may be a leading cause of COVID-19, and could potentially slow its transmission. Dr. Peters is also a recent recipient of COVID-19 Rapid Research Funding sponsored by the Office of the Vice President for Research and Innovation and the C. Kenneth and Dianne Wright Center for Clinical and Translational Research. Dr. Peters currently serves as a member of the Developmental Therapeutics research program at VCU Massey Cancer Center and professor in the Department of Chemical and Life Science Engineering at the VCU College of Engineering.